AstraZeneca's investigational drug, sipavibart, has shown promising results in a late-stage study, meeting its primary goals in preventing COVID-19 in immunocompromised patients. The drug significantly reduced the risk of infection in patients with weaker immunity and met dual endpoints. This comes as AstraZeneca's globally used COVID-19 vaccine faces scrutiny due to links with rare blood disorders, including rare blood clots and a 'common cold' blood disease. Researchers have identified an autoimmune reaction as the cause of these rare blood clots in some individuals predisposed to such conditions.
AstraZeneca said that a new long-acting antibody reduced immunocompromised patients’ risks of contracting symptomatic Covid-19 infections in a large Phase 3 prevention trial. Still, it’s not clear whether the new… https://t.co/T5GRnSYzJs
#AstraZeneca's #COVID19 prevention drug cuts risk of disease in vulnerable patients https://t.co/zXRFkC6Lf8
Covid Vaccines Linked to Rare Type of Deadly Abdominal Blood Clots — Study https://t.co/4KzuY9rYTK
Scientists uncover link between Covid vaccination and rare 'common cold' blood disease https://t.co/p8Fs0OMm9U
AstraZeneca's latest study reveals promising results, showing that Sipavibart significantly reduces the risk of COVID-19 in immunocompromised patients. The drug meets dual endpoints, offering hope in the fight against the ongoing pandemic. $AZN
While AstraZeneca’s globally used COVID-19 vaccine is leaving the scene, the British Big Pharma is hoping it will be taking a fresh therapeutic option to regulators soon. $AZN https://t.co/x8w6D5JcmY
AstraZeneca’s COVID prevention drug cuts risk of disease #ARYNews https://t.co/ZHUOIzdmhP
AstraZeneca's COVID-19 prevention therapy reduced the risk of infection in patients with weaker immunity in a late-stage trial, meeting its primary goal, the drugmaker said on Thursday. https://t.co/XjiNud71WT https://t.co/XjiNud71WT
#AstraZeneca's Covid vaccine linked to another rare blood disorder https://t.co/pBQCjpEJlJ
AstraZeneca's COVID prevention drug meets primary goals in late-stage study https://t.co/E7zjm5Oy9E https://t.co/WYDgSrRWrL
AstraZeneca said on Thursday its investigational drug, sipavibart, met primary goals in preventing COVID-19 in immunocompromised patients in a late-stage trial. https://t.co/6vi7PjrSXK https://t.co/6vi7PjrSXK
Rare blood clots tied to J&J and AstraZeneca's Covid-19 shots were caused by an autoimmune reaction that some people are predisposed to, researchers found https://t.co/LpUw0W2cKa